Furthermore, clinical studies have demonstrated that patients receiving recombinant human erythropoietin once, twice or three times per week may be converted to a once-weekly or a once-every-other-week regimen of Aranesp. In such cases, the initial weekly dose of Aranesp in microgram per week, can be determined by dividing the total weekly dose of recombinant human erythropoietin in IU/week by 200. Similarly, the initial alternate weekly dose of Aranesp in microgram every other week, can be determined by dividing the total dose of recombinant human erythropoietin in IU over a two-week period by 200.
In all patients, haemoglobin should be monitored every one or two weeks and subsequent dosing titrated individually as necessary to maintain the haemoglobin target.
Further information: Amgen Ltd, 240 Cambridge Science Park, Milton Road, Cambridge CB2 4LX. Tel: (01223) 420305.